The population-based prevalence of trachomatous scarring in a trachoma hyperendemic setting: results from 152 impact surveys in Amhara, Ethiopia.


Journal

BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802

Informations de publication

Date de publication:
13 May 2021
Historique:
received: 13 11 2020
accepted: 28 04 2021
entrez: 14 5 2021
pubmed: 15 5 2021
medline: 18 5 2021
Statut: epublish

Résumé

Trachomatous scarring (TS) results from repeated infection with the bacterium Chlamydia trachomatis. Pronounced scarring is an underlying cause of trachomatous trichiasis (TT) that can lead to blindness. Since the condition is irreversible, TS in adults has been considered a marker of past exposure to trachoma infection. The aim of this report was to estimate the population-based prevalence of TS within Amhara, Ethiopia, a region with a historically high burden of trachoma. District-level multi-stage cluster surveys were conducted in all districts between 2010 and 2015 to monitor the impact of approximately 5 years of trachoma interventions. Approximately 40 households were sampled per cluster and all participants ages ≥ 1 year were graded for the 5 World Health Organization simplified signs. Before each survey round, trachoma graders participated in a 7-day training and reliability exam that included cases of TS. TS prevalence estimates were weighted to account for sampling design and adjusted for age and sex using post-stratification weighting. Across the 152 districts in Amhara, 208,510 individuals ages 1 year and older were examined for the signs of trachoma. Region-wide, the prevalence of TS was 8.2 %, (95 % Confidence Interval [CI]: 7.7-8.6 %), and the prevalence among individuals ages 15 years and older (n = 110,137) was 12.6 % (95 % CI: 12.0-13.3 %). District-level TS prevalence among individuals ages 15 years and older ranged from 0.9 to 36.9 % and was moderately correlated with district prevalence of TT (r = 0.31; P < 0.001). The prevalence of TS increased with age, reaching 22.4 % among those ages 56 to 60 years and 24.2 % among those ages 61 to 65 years. Among children ages 1 to 15 years TS prevalence was 2.2 % (95 % CI: 1.8-2.8 %), increased with age (P < 0.001), and 5 % of individuals with TS also had trachomatous inflammation-intense (TI). These results suggest that Amhara has had a long history of trachoma exposure and that a large population remains at risk for developing TT. It is promising, however, that children, many born after interventions began, have low levels of TS compared to other known trachoma-hyperendemic areas.

Sections du résumé

BACKGROUND BACKGROUND
Trachomatous scarring (TS) results from repeated infection with the bacterium Chlamydia trachomatis. Pronounced scarring is an underlying cause of trachomatous trichiasis (TT) that can lead to blindness. Since the condition is irreversible, TS in adults has been considered a marker of past exposure to trachoma infection. The aim of this report was to estimate the population-based prevalence of TS within Amhara, Ethiopia, a region with a historically high burden of trachoma.
METHODS METHODS
District-level multi-stage cluster surveys were conducted in all districts between 2010 and 2015 to monitor the impact of approximately 5 years of trachoma interventions. Approximately 40 households were sampled per cluster and all participants ages ≥ 1 year were graded for the 5 World Health Organization simplified signs. Before each survey round, trachoma graders participated in a 7-day training and reliability exam that included cases of TS. TS prevalence estimates were weighted to account for sampling design and adjusted for age and sex using post-stratification weighting.
RESULTS RESULTS
Across the 152 districts in Amhara, 208,510 individuals ages 1 year and older were examined for the signs of trachoma. Region-wide, the prevalence of TS was 8.2 %, (95 % Confidence Interval [CI]: 7.7-8.6 %), and the prevalence among individuals ages 15 years and older (n = 110,137) was 12.6 % (95 % CI: 12.0-13.3 %). District-level TS prevalence among individuals ages 15 years and older ranged from 0.9 to 36.9 % and was moderately correlated with district prevalence of TT (r = 0.31; P < 0.001). The prevalence of TS increased with age, reaching 22.4 % among those ages 56 to 60 years and 24.2 % among those ages 61 to 65 years. Among children ages 1 to 15 years TS prevalence was 2.2 % (95 % CI: 1.8-2.8 %), increased with age (P < 0.001), and 5 % of individuals with TS also had trachomatous inflammation-intense (TI).
CONCLUSIONS CONCLUSIONS
These results suggest that Amhara has had a long history of trachoma exposure and that a large population remains at risk for developing TT. It is promising, however, that children, many born after interventions began, have low levels of TS compared to other known trachoma-hyperendemic areas.

Identifiants

pubmed: 33985443
doi: 10.1186/s12886-021-01972-w
pii: 10.1186/s12886-021-01972-w
pmc: PMC8120834
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

213

Références

Ophthalmology. 2011 Apr;118(4):747-54
pubmed: 21055819
Trans R Soc Trop Med Hyg. 2009 Oct;103(10):1001-10
pubmed: 19178920
Ophthalmic Epidemiol. 2001 Jul;8(2-3):137-44
pubmed: 11471083
Lancet. 1993 Aug 21;342(8869):453-6
pubmed: 8102427
Clin Infect Dis. 2018 Nov 28;67(12):1840-1846
pubmed: 29741592
PLoS Negl Trop Dis. 2008 Sep 24;2(9):e299
pubmed: 18820746
PLoS Negl Trop Dis. 2009 Jun 16;3(6):e462
pubmed: 19529762
Trans R Soc Trop Med Hyg. 2018 Dec 01;112(12):538-545
pubmed: 30265355
PLoS Negl Trop Dis. 2015 May 13;9(5):e0003763
pubmed: 25970613
Invest Ophthalmol Vis Sci. 2009 Feb;50(2):592-6
pubmed: 18936137
J Antimicrob Chemother. 2005 Jan;55(1):10-21
pubmed: 15590715
Ophthalmology. 2009 Feb;116(2):243-7
pubmed: 19091415
Ophthalmic Epidemiol. 2015;22(3):214-25
pubmed: 26158580
PLoS Negl Trop Dis. 2019 Aug 14;13(8):e0007638
pubmed: 31412025
PLoS Negl Trop Dis. 2014 Mar 13;8(3):e2732
pubmed: 24625539
PLoS Negl Trop Dis. 2014 Jun 26;8(6):e2900
pubmed: 24967629
PLoS Negl Trop Dis. 2008 Mar 19;2(3):e197
pubmed: 18350115
PLoS One. 2013 Sep 16;8(9):e74570
pubmed: 24066147
Ophthalmology. 2001 Dec;108(12):2219-24
pubmed: 11733262
PLoS Negl Trop Dis. 2016 Aug 02;10(8):e0004859
pubmed: 27483002
Am J Trop Med Hyg. 2019 Dec;101(6):1286-1295
pubmed: 31549612
Ophthalmic Epidemiol. 2015;22(6):394-402
pubmed: 26653262
Am J Trop Med Hyg. 2019 Dec;101(6):1296-1302
pubmed: 31595874
Clin Infect Dis. 2020 Aug 10;:
pubmed: 32776137
Ophthalmic Epidemiol. 2007 Sep-Oct;14(5):267-72
pubmed: 17994435
Wellcome Open Res. 2018 Feb 22;3:14
pubmed: 29588922
Br J Ophthalmol. 2018 Apr;102(4):419-423
pubmed: 29306862
Trop Med Int Health. 1997 Nov;2(11):1030-8
pubmed: 9391505
Invest Ophthalmol Vis Sci. 2011 Apr 06;52(5):2181-6
pubmed: 21178143
PLoS Negl Trop Dis. 2020 Oct 5;14(10):e0008708
pubmed: 33017417
Bull World Health Organ. 1987;65(4):477-83
pubmed: 3500800
PLoS Negl Trop Dis. 2017 Jun 14;11(6):e0005658
pubmed: 28614375

Auteurs

Tigist Astale (T)

The Carter Center, Addis Ababa, Ethiopia.

Caleb D Ebert (CD)

F.I. Proctor Foundation, University of California, San Francisco, CA, San Francisco, USA. caleb.ebert@cartercenter.org.

Andrew W Nute (AW)

The Carter Center, GA, Atlanta, USA.

Mulat Zerihun (M)

The Carter Center, Addis Ababa, Ethiopia.

Demelash Gessese (D)

The Carter Center, Addis Ababa, Ethiopia.

Berhanu Melak (B)

The Carter Center, Addis Ababa, Ethiopia.

Eshetu Sata (E)

The Carter Center, Addis Ababa, Ethiopia.

Zebene Ayele (Z)

The Carter Center, Addis Ababa, Ethiopia.

Gedefaw Ayenew (G)

The Carter Center, Addis Ababa, Ethiopia.

E Kelly Callahan (EK)

The Carter Center, GA, Atlanta, USA.

Mahteme Haile (M)

Amhara Public Health Institute, Bahir Dar, Ethiopia.

Taye Zeru (T)

Amhara Public Health Institute, Bahir Dar, Ethiopia.

Zerihun Tadesse (Z)

The Carter Center, Addis Ababa, Ethiopia.

Scott D Nash (SD)

The Carter Center, GA, Atlanta, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH